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Novel psychoactive substances (NPS) have been a part of the landscape of clinical and forensic 
toxicology for over a century, beginning with the introduction of a few new drugs like heroin, 
lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and gamma-
hydroxybutyric acid (GHB). However, after the appearance of synthetic cannabinoids in the 
early 2000’s there was a rapid emergence of hundreds of synthetic cathinones, benzodiazepines 
and opioids. Toxicology laboratories previously focused on a rather narrow range of compounds 
including amphetamines, cannabinoids, cocaine, opioids, antidepressants, salicylate and 
acetaminophen. Now potent fentanyl derivatives are mixed with heroin or substituted entirely, 
killing unsuspecting drug users at an alarming rate. Toxicology laboratories are challenged with 
detecting potent drug analogs that are only present in blood for a short period of time, urinary 
metabolites whose chemical formula and structures are initially unknown, and no available 
reference standards. Here four international experts discuss what fueled the global NPS market, 
how toxicology laboratories can best address this challenge, and how public health and law 
enforcement agencies can help reduce the morbidity and mortality associated with NPS. 
 
What factors contributed to the explosion of NPS onto the recreational drug market? 
 
Simon D. Brandt: There are important factors that contributed to this phenomenon but advances 
in information technology and communication and globalized trade were crucial. Entrepreneurs 
are now able to instruct contract synthesis laboratories overseas (often in China) to produce any 
compound of choice on a large scale and in high purity at low cost. From the perspective of a 
service provider, for example one specialized in the manufacturing of chemicals, the nature of 
synthesized compounds does not necessarily make any difference and some laboratories are well 
equipped to supply high quality pharmaceutical drugs and NPS alike. Once the demand is 
identified, product diversification and expansion of product catalogues follow, which are then 
available to prospective clients. Easy access to specialist and research literature from the comfort 
of one’s living room facilitates the process by paving the way for new ideas. Electronic 
commerce is a powerful force that permeates our societies and impacts on how we deal with 
goods and services, but also on information exchange. As with any other commodity, drugs may 
be purchased via the ‘visible’ Internet or the ‘dark web’, where the latter also includes the trade 
of controlled substances. Legislative ambiguity in how to deal with the NPS phenomenon and 
the supply of these substances is also an important consideration. In addition, trading within a 
globalized world allows for highly effective ways to supply and distribute the goods so they can 
reach any corner of the world relatively easily. In cases where organized crime groups are 
involved in distribution to end users, a wider penetration to distinct sub-populations may also be 
achieved. In previous decades, information and supply of then non-controlled alternatives to 
some of the ‘classic’ drugs, including natural products, originated from specialized mail order 
catalogues, flyers or magazine advertisements, which also limited access to specialized 
communities. Today, your mobile phone assists you in accessing this information, placing an 
order and sharing your experiences on a user forum.  
 
Suman Rana: Multiple factors contributed to the explosion of NPS into the recreational drug 
market. First and foremost, in my opinion, was the widespread availability of Internet shopping. 
Internet shops made NPS just a “click” away from the experimental drug users and fueled the 
NPS explosion. Other factors included the ease of synthesis and alteration of molecular 
structures of existing drugs to circumvent regulations. Lack of effective and timely regulation 
made it easy for clandestine drug manufacturers to stay ahead of regulation as the drug culture 
started shifting.  The ineffective control over NPS, not only in the United States but also in 
nations like China and India where the vast majority of synthesis for these chemicals occurs, 
played a huge role in their increasing prevalence. Effective control over their manufacturing 
could not be implemented, which, coupled with easy Internet channels for sale, resulted in a huge 
explosion. Because NPS were not effectively regulated, they became attractive to adolescents 
and young adults, particularly those seeking to avoid a positive drug screen. Other factors 
included similarity in their effects to some of the existing drugs. For example, the first generation 
synthetic cannabinoids mimicked the effects of marijuana and quickly gained popularity as 
“Legal Pot”. However, as the chemical composition of NPS continued to evolve, so did their 
physiological effects. 
 
Michael H. Baumann: Information freely available on the Internet is a major contributor to the 
explosion of NPS.  Electronic biomedical databases provide information about the central 
nervous system (CNS) targets for drugs of abuse, such as neuroreceptors and transporters. Online 
chemistry journals and patent literature give detailed recipes for synthesizing compounds that 
interact at these targets with high potency and efficacy.  Commercial websites provide easy 
marketing and sales of anonymous purchases, facilitating global availability of NPS.  Finally, 
online user forums provide a platform for information sharing among those users who seek to 
fine tune their drug-taking experiences. 
 
Volker Auwärter: A prerequisite for the phenomenon was the introduction of online retail 
markets for drugs and the resulting high availability, combined with transfer of information on 
new drugs via social media and, in particular, online drug forums. Relatively high prices and 
often low quality of classical illegal drugs, particularly in rural regions, may also have 
contributed. Finally, the degree of repression on drug users (comprising extensive ‘work place 
drug testing’ programs and driving license issues) and the legal status of NPS certainly 
influenced the dynamics. 
 
What are the advantages and disadvantages to drug users of taking NPS rather than classical 
drugs?  
 
Suman Rana: The obvious advantage to the users is their easy availability and avoidance of 
detection during a routine drug test since most drug testing programs do not include NPS in their 
testing profile. Even if programs mandated testing for NPS, there are a limited number of 
laboratories that have the capability to develop testing to detect the ever-changing chemicals. In 
addition, the legal status of many of these drugs makes NPS a favorable choice over classical 
drugs since there are no legal repercussions for using something that is not controlled. 
 
Disadvantages of using NPS are mainly the toxicity associated with their use, and the lack of 
toxicity studies prior to their introduction in the market. In the absence of such data, users are 
literally playing with their life since the harmful effects are not well known and/or understood. 
Another disadvantage is the lack of quality control in the manufacturing process of products 
containing NPS. NPS-laced products are prepared in clandestine laboratories where product 
consistency is not maintained, resulting in “hot spots” within the product where drug 
concentration may be much higher than other parts of the same preparation. As a result, the user 
may experience acute toxic effects due to an increased dose. 
 Michael H. Baumann: NPS are cheap, easy to obtain, and not detected by traditional drug 
screening methods, which rely on antibody-based technologies that recognize only a few specific 
drugs and their metabolites.  A major driving force for the misuse of NPS is their lack of 
detection, especially in those populations that are subjected to routine toxicology screening (e.g., 
military personnel, parolees, probationers).  A major disadvantage of using NPS is the risk for 
adverse effects since the active ingredients in the products are often unknown, and the biological 
effects of most NPS have not been evaluated in animal experiments.  To date, no controlled 
clinical trials have examined the effects of NPS in human subjects. 
 
Volker Auwärter: The advantages include high availability, relatively low prices, low risk of 
being prosecuted, wide variety of drugs for experimental drug use, online shopping rating 
systems, exchange in online forums (e.g. on quality of drugs and reliability of suppliers), and no 
personal contact with potentially dangerous drug dealers. 
 
The disadvantages include a greater risk of new compounds due to lack of experience and 
knowledge on specific toxicity (resulting in relatively high numbers of intoxications/deaths), 
greater difficulties in judging identity and/or purity of the drugs, and greater problems regarding 
drug dosing. 
 
Simon D. Brandt: NPS are often easier to obtain, and the context in which a particular NPS is 
taken might also be relevant. Although access to classical controlled drugs does not appear to be 
a problem in many countries, some users may not wish to engage with the friendly street dealer 
around the corner and are, therefore, looking for non-controlled substances and/or other sources 
of supply. Others might wish to obtain alternatives to CNS-active medicines that are available on 
prescription only. This can be a challenge for patients who received prescription drugs for a 
limited amount of time, but who might wish to continue with the drug treatment without medical 
supervision. Individuals who contemplate use of alternatives to prescription drugs without 
consulting a healthcare professional have access to a range of NPS classes that might serve their 
needs, either for recreational or self-medication purposes. There is a fraction of users who are 
solely interested in the exploration of new chemical entities and desire NPS primarily for their 
novelty. The fast rate at which NPS arrive on the drug market can place significant challenges on 
the ability to detect them within the clinical and forensic setting, and users who might wish to 
avoid drug detection stand a better chance of being successful. Overall, it is still a challenge to 
obtain accurate information about the scale of NPS use in the general population and how this 
compares with traditional drugs that appear to dominate the scene. However, there is a segment 
of society that appears to be more prone to NPS exposure compared to the general population, 
including those with a history of problematic drug use, homelessness or mental health problems, 
or prison service users. The difficulty encountered in drug detection may be an advantage for 
some of these users but ultimately drug consumption under these conditions is essentially driven 
by which drugs are available rather than choice.  
 
Synthetic cannabinoids initially led the introduction of NPS, but currently NPS are available 
for almost all drug classes. Do you think we will continue to see the introduction of new NPS 
in all drug classes and why? 
 
Michael H. Baumann: It seems certain that NPS that mimic the effects of all major classes of 
abused drugs will continue to be available.  In this regard, the most alarming new trend is the 
appearance of various novel synthetic opioids (NSO) in the street drug marketplace.  NSO 
include high-potency analogs of fentanyl such as acetylfentanyl, butyrylfentanyl, and 
furanylfentanyl, as well as non-fentanyl analogs like U-47700 and MT-45.  These substances are 
contributing to the current spike in opioid overdose deaths.  NSO are synthesized in Asian 
laboratories and marketed via the Internet, similar to the pathway for manufacture and sale of 
cathinone and cannabinoid NPS.  NSO are now present in the street drug marketplace as stand-
alone products, adulterants in illicit heroin, and counterfeit opioid medications.  Most users are 
completely unaware of their exposure to NSO.  The continued spread of synthetic opioids 
represents a significant public health threat. 
 
Volker Auwärter: Yes, I do think so, basically because there will be an ongoing demand for 
new compounds due to legislative regulations, and there is a lot of money to be made in this 
market. In different countries, there will certainly be different drug preferences depending on 
cultural circumstances, as well as availability, quality, prices, and law enforcement pressure on 
classical illegal drugs. 
 
Simon D. Brandt: The introduction of NPS is largely driven by what is manufactured in 
contract synthesis laboratories that treat these compounds like any other saleable chemical and 
where diversification of the product portfolio increases further business opportunities. The 
development of NPS that are emerging onto the market reflects modifications of known, or 
classical chemical structures with psychoactivity. The plethora of analogs and derivatives that 
can theoretically arise from endless permutations has not yet been exhausted and one can 
envisage many more candidates that could still be released. Another approach to exploring 
potential NPS ideas may be linked to the identification of primary pharmacological targets that 
are correlated with CNS activity. This might well be an important area for further investigation. 
In pharmaceutical drug development, structurally diverse compounds are investigated for their 
ability to produce desired CNS effects through agonism or antagonism at specific biological 
targets. Clandestine NPS producers appear to be adopting this approach. It seems likely that the 
number of potentially available NPS will increase if large-scale manufacturing facilities continue 
to exist. At the same time, one must realize that not every developed compound leads to the 
desired psychoactive effects in humans, which might explain in part why the existence of many 
compounds on the market has been short-lived.  
 
Suman Rana: Yes, I do think that we will continue to see the introduction of new NPS in all 
drug classes. The scientific communities are trying to do a better job of disseminating 
information about NPS, and the regulatory agencies are constantly trying to make regulations 
more effective, so it is imperative that clandestine drug manufacturers continue to market more 
NPS across all drug classes to stay one step ahead of the regulations. Manufacturing NPS is a 
lucrative business for drug-making laboratories, so they will not quit easily. 
 
What tools do toxicology laboratories need to best identify NPS intake in biological 
specimens? Should all laboratories offer these services or is it a better allocation of resources 
for reference or centralized laboratories to offer NPS testing? 
 
Volker Auwärter: At the moment, I believe that the most efficient strategy consists of having 
regularly updated and targeted LC-MS/MS methods. To keep the methods up to date, a 
continuous market monitoring combined with tools for identification of the main metabolites is 
required. Incubation of NPS with prepared human liver microsomes and identification human 
urinary metabolites by mass spectrometry is the most cost effective technique of several 
available approaches. Given the relatively low general prevalence of NPS in most countries, the 
time-consuming and expensive efforts required to keep pace with market developments, and the 
extensive analytical expertise required, I believe that centralized laboratories will be the more 
effective solution.  
 
Simon D. Brandt: Implementation of gas and liquid chromatography-based techniques coupled 
to various mass analyzers (including single stage, MS/MS and/or MSn) with low and high 
resolution appear to be essential tools. The key challenge is to unambiguously identify NPS in a 
practical timeframe. Many laboratories struggle to do this task, particularly in the absence of 
reference material that may be included in the corresponding screening procedures. Lack of 
specific instrumentation, however, might also contribute to this challenge, especially when 
dealing with low NPS concentrations. The idea of centralized laboratories that specifically deal 
with NPS cases is an interesting option, which could alleviate the burden faced by some forensic 
providers provided this is carried out in a timely fashion. Centralized collection of data might 
also help to minimize the problem of underreporting. In some countries, publicly-funded and 
centralized laboratories that deal with forensic and clinical casework exist, which has the 
advantage that a more complete picture can be painted regarding acute toxicity induced by NPS 
currently circulating on the market. At the same time, the reliance on a limited number of 
laboratories that dominate the market place might be a cause for concern to others. Toxicology 
laboratories could perhaps also benefit from small- or micro-scale organic synthesis facilities to 
improve analysis capability by supplying reference materials for NPS and their metabolites. 
 
Suman Rana: Laboratories need analytically sensitive instrumentation for detection, parent drug 
and metabolite reference standards for identification, and qualified staff to develop methods for 
analysis of NPS in biological matrices and provide interpretation of these data. Unfortunately, 
most public sector laboratories do not have funds to acquire expensive instrumentation or 
research staff. Laboratories that have such resources should offer these services. For others, there 
needs to be reference or centralized laboratories where testing could be outsourced. 
 
Michael H. Baumann: High volume standard toxicology screening methods for the detection of 
abused drugs have relied on antibody-based technologies (e.g., immunoassays), which can 
identify a limited number of drugs and their metabolites.  Such tests do not detect the presence of 
most NPS.  Given the rapid appearance and disappearance of NPS in the marketplace, the 
expensive and cumbersome process of developing new immunoassays cannot keep pace.  Thus, 
more sophisticated analytical methods such as liquid chromatography with mass spectrometry or 
high-resolution mass spectrometry are required to detect newly emerging drugs.   
 
Human hepatocyte incubations and high resolution mass spectrometric identification of 
urinary NPS metabolites, and verification of identified markers in authentic urine specimens 
is necessary to identify NPS intake and to provide data to commercial standard manufacturers 
for the targeted synthesis of reference standard metabolites. Is this a feasible approach to keep 
pace with the rapidity of NPS introduction? 
 
Simon D. Brandt: The evaluation of various cellular preparations is helpful to identify urinary 
markers and how verification can be obtained from authentic urine samples. It is therefore an 
important source of information to guide the targeted synthesis of metabolites. An alternative 
approach to the identification of human urinary markers, although admittedly less common, may 
involve self-experiments. For the purpose of metabolism studies, an ingested dose might fall 
below what might be considered an active dose, thus, reducing or avoiding psychoactive effects. 
Generally speaking, important key metabolites may be predictable, either with or without support 
from in silico studies, so commercial suppliers may not be limited anymore by the unavailability 
of these data. Cost implications may also be relevant. There are cases where distinct NPS can 
result in the formation of identical transformation products, so the search for potentially 
distinctive candidates could also be a fruitful area of investigation. The search for biological 
markers arising from potential synthesis impurities present in NPS might also deserve some 
attention.  
 
Suman Rana: In my opinion, this is not the most effective approach to keep pace with the 
rapidity of NPS introduction. While it is a necessary approach for urine drug testing, the use of 
alternate matrices like oral fluid is a much better approach for effective monitoring and testing 
for NPS. The time and resources involved in identifying the urinary metabolites, synthesizing the 
identified metabolites to be used as a reference standard in routine testing, and developing 
complex methods of testing capable of identifying multiple metabolites is futile, because new 
NPS are introduced so rapidly into the market that by the time the method is developed and 
implemented it is no longer effective. This whole process is detrimental to any laboratory. Since 
parent drugs are detected in oral fluid, there is no need to spend time and resources in identifying 
the metabolites. Drug reference standards are more rapidly available for parent drugs so the 
methods for detection can be developed relatively easily. The interpretation of a urine test could 
also be challenging.  Since the NPS are produced by slight modifications of the existing drug 
structures, many of them produce metabolites common to multiple drugs, thus complicating 
interpretation since it is challenging to identify the parent drug consumed.  In contrast, oral fluid 
testing allows identification of the parent compound. It is much easier for laboratories to stay 
current with the drug market by using oral fluid testing. 
 
Michael H. Baumann: Urinary detection of NPS and their metabolites will continue to be a 
main source of information, but human specimens are not readily available in many research 
settings.  Additional strategies for investigating the metabolism of NPS are available.  In vitro 
metabolism studies using prepared human liver microsomes or hepatocytes can provide useful 
data about the metabolism of NPS.  Likewise, in vivo experiments in animal models can also be 
important because only a few of the many potential metabolites generated in vitro are present 
after NPS administration in vivo.  As an example, the synthetic cannabinoid AM-2201 generated 
13 different metabolites when examined in vitro, but only three of these metabolites were 
detected after in vivo administration of AM-2201 to rodents. Therefore, combined in vitro and in 
vivo approaches can be useful for predicting metabolic profiles for NPS as they emerge. 
 
Volker Auwärter: I would slightly disagree, because marker identification can also be 
performed effectively by using prepared human liver microsome assays, which are less 
expensive and time consuming. In addition, pure reference standards of metabolites are 
useful for quantitative analysis but not necessarily needed for an unambiguous proof of 
drug intake. Nevertheless, quick identification of valid consumption markers is essential 
and has proved to be feasible.  
 
High-resolution mass spectrometry (HRMS) is an important tool to combat the 
problem of NPS. How do you use HRMS in your laboratory, and do you think that 
HRMS will be an essential tool for all laboratories within 5 years? 
 
Suman Rana: HRMS systems are important but not essential to combating the NPS problem. 
While high-resolution systems provide important structural information about the NPS 
metabolites and help with initial method development, once that information is available the 
analysis could be performed using nominal mass analyzers. I think HRMS is an essential tool for 
understanding and identifying the urinary metabolites for new drugs and should be used at 
reference or centralized laboratories that are engaged in metabolite identification studies for the 
new NPS; however, having HRMS systems in every laboratory and having qualified staff to 
interpret the HRMS data at every laboratory in the next 5 years is not realistic or necessary. My 
laboratory is one of the leading laboratories in the United States that provides NPS testing but 
currently we do not have an HRMS system. We send our hepatocyte or microsome incubation 
samples out to other reference laboratories for structure elucidation/identification for initial 
method development. 
 
Michael H. Baumann: Novel mass spectrometry methods such as sequential window 
acquisition of all theoretical mass spectra (SWATH) can be used to accurately measure many 
NPS and their metabolites in a single confiscated drug product or biological specimen. One of 
the chief advantages of SWATH is that the method can be continuously updated for the detection 
of a diverse panel of analytes to keep pace with the changing street drug landscape. 
 
Volker Auwärter: We use HRMS mainly for confirmation of tentatively identified metabolites 
and to screen biological samples in specific cases where we suspect compounds not covered by 
our routine NPS methods. I believe that in 5 years most of the workload of clinical and forensic 
laboratories will still be processed without HRMS. Nevertheless, the technique offers great 
added value and will become standard as soon as prices have come down to be comparable to 
those of high-end triple quadrupole instruments and the software tools have improved (e.g. 
reliable, semi-automated data analysis). 
 
Simon D. Brandt: HRMS has indeed helped with the increase of information content, most 
notably when detecting potential drug candidates that have not been seen previously. In these 
situations, the combination of high-resolution single- and tandem-mass spectrometry facilitates 
the identification process or helps to narrow down potential candidates that are consistent with 
the molecular formulae obtained from the protonated molecule (in positive mode), but also from 
the resulting high-resolution product ions that support the formulation of dissociation pathways. 
Important information can be derived from using low-resolution approaches as well, but the 
high-resolution option provides more confidence in the interpretation. Whether HRMS should be 
considered an essential tool remains to be seen, but it seems likely that increasing popularity 
combined with lower pricing will contribute to a further expansion of this method of analysis. In 
part, this is also driven by specific marketing efforts by manufacturers of HRMS products. 
Implementation of new technologies, for example in the form of instrumentation and novel 
software applications, will always be needed and the expertise and experience gained by the 
analyst will maximize their impact. 
 
What do you think is the best strategy for local, state, and federal laboratories to address the 
problem of NPS? 
 
Michael H. Baumann: NPS often cause localized epidemics of toxic exposures, where many 
patients simultaneously present to emergency departments exhibiting life-threatening adverse 
medical symptoms.  In many cases, the precise chemical compounds causing the medical 
emergency are not known because typical hospital settings do not have the sophisticated 
analytical technology available for identifying NPS, especially when new drugs first appear on 
the market.  Creating a network of regional sentinel laboratories across the United States could 
provide rapid and accurate forensic analysis of confiscated products and biological specimens 
when epidemics of NPS first arise. These laboratories should have the infrastructure and staffing 
needed to perform a variety of mass spectrometry methods. The resulting analytical findings 
could be shared in an open-access online format to allow instant access for all stakeholders of 
interest, including clinical toxicologists, research scientists, and law enforcement personnel. 
 
Volker Auwärter: The worst strategy is to close one’s eyes and neglect the problem, because 
this will inevitably lead to a considerable number of undetected NPS in case work. It is also not 
sufficient to implement methods targeting a range of compounds without being updated regularly 
according to the drug market scene. Therefore, a few specialized laboratories should thoroughly 
tackle the problem, provide comprehensive methods, and offer their service to other local 
laboratories. This applies in particular to forensic case work, where missing a compound or 
producing a ‘false positive’ may have serious consequences. 
 
Simon D. Brandt: Toxicology laboratories play a crucial role in the assessment of identifying 
acute harms that might be associated with NPS use. The provision of real-time information can 
form part of NPS toxicovigilance that is needed to inform policymakers and other stakeholders 
faced with this phenomenon. Technological challenges aside, perhaps one of the most important 
strategies is to facilitate fast, effective, and unbiased information exchange and data 
dissemination so that effective response to this dynamic drug market can be formulated in 
conjunction with public healthcare and harm reduction professionals. A key emphasis here is the 
contribution to an early-warning system. 
 
Suman Rana: This is a difficult question. The only way I see local and state laboratories 
managing the NPS problem is by sending out testing to reference or centralized facilities. 
Investment in centralized laboratories is necessary to establish testing protocols and to support 
ongoing research needed to keep up with the changing drug scene. Updating the testing 
procedures on an ongoing basis to include the most current drugs is essential for successful 
handling the NPS problem. Having the centralized laboratories capable of keeping the testing 
protocols updated will ensure successful detection of NPS cases. 
 
 
 




